Retrospective Study
Copyright ©The Author(s) 2017.
World J Gastrointest Oncol. Oct 15, 2017; 9(10): 416-422
Published online Oct 15, 2017. doi: 10.4251/wjgo.v9.i10.416
Table 1 Patient characteristics n (%)
Older group (n = 64)Non-older group (n = 168)P value
Mean age84.269.5
Gender ratio (M/F)44/20118/50NS
No. of performance state 3 or 45 (7.8)4 (2.4)
Pre-existing comorbidity
Total prevalence rates58 (90.6)123 (73.2)0.0042
Cerebral infarction11 (17.2)17 (10.1)NS
Cardiovascular disease23 (35.9)25 (14.9)0.0004
Respiratory disease8 (12.5)12 (7.1)NS
Chronic renal dysfunction8 (12.5)21 (12.5)NS
Liver cirrhosis1 (1.6)12 (7.1)NS
Diabetes20 (31.2)47 (28.0)NS
Hypertension44 (68.8)98 (58.3)NS
Senile dementia7 (10.9)14 (8.3)NS
Anti-coagulant therapy4 (6.3)12 (7.1)NS
Table 2 Tumors characteristics
Older group (n = 64)Non-older group (n = 168)P value
Location
Upper28390.019
Middle1655NS
Lower2072NS
Residual stomach02
Mean tumor size17.515.6NS
Histological type
Well differentiated58149NS
Moderately differentiated510NS
Poorly differentiated08NS
Papillary differentiated11NS
Category of indication
Guideline lesion47118NS
Lesion included in the expanded indications1750NS
Table 3 Technical outcome n (%)
Older group (n = 64)Non-older group (n = 168)P value
En bloc resection63 (98.4)168 (100)NS
R0 resection61 (95.3)168 (100)0.03
Complications
Intraoperative hemorrhage0 (0)0 (0)NS
Intraoperative perforation1 (1.6)0 (0)NS
Postoperative hemorrhage1 (1.6)8 (4.8)NS
Postoperative perforation0 (0)0 (0)NS
Table 4 Social and economic outcomes n (%)
ParameterOlder group (n = 64)Non-older group (n = 168)P value
Worsening of the performance status3/64 (4.7)1/168 (0.6)NS
Mean duration of hospitalization (d)11.410.7NS
Mean financial cost of admission (JPY)657040574890NS